Biologic and synthetic skin substitutes
Ask the expert
The report presents a summary of reimbursement situation for use of biologic and synthetic skin substitutes in European countries.
Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations).
The following clinical indications will be considered:
- chronic wounds (hypertrophic scar).
The only reimbursement within public / statutory health insurance systems is considered.
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- England (UK)
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of biologic and synthetic skin substitutes include:
- Allergan (AlloDerm)
- Anika Therapeutics (HYALOMATRIX)
- Avita Medical (ReCell)
- Eurosurgical (Pelnac)
- Hans Biomed (SureDerm)
- Integra LifeSciences (Dermal Regeneration Template)
- MedSkin Solutions (MatriDerm)
- MiMedx Group (AmnioFix, EpiFix, EpiBurn, AmnioCord, AmnioFill)
- Modex Therapeutiques (EpiDex)
- Olympus Terumo Biomaterials (Terudermis)
- Organogenesis (Dermagraft, NuShield, Affinity, Apligraf)
- Ortec International (OrCel)
- Osiris Therapeutics (Grafix, Grafix PL prime)
- Promethean LifeSciences (GammaGraft)
- Regenicin (PermaDerm)
- Smith & Nephew (Biobrane, Oasis, Oasis Ultra)
- Stryker (DermACELL)
- Vericel Corporation (Epicel)
- Wright Medical (GRAFTJACKET)
Table of content is not available at the moment. Report is still ongoing.
In May 2022, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedure Guidance (endoanchoring systems in endovascular aortic aneurysm repair, supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis, personalized external aortic root support using mesh in people with Marfan syndrome), one Medical Technologies Guidance (Sleepio to treat insomnia and insomnia symptoms), and six Medtech innovation Briefings (ViewSite Brain Access System, Granulox for managing chronic wounds, AMBLor for identifying melanomas, Bladder EpiCheck for detecting bladder cancer recurrence, and others). No MedTech-related clinical guidelines were published.Read more
In June 2021, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (laser lithotripsy for difficult-to-treat bile duct stones and percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve), one new Medical Technologies Guidance (Plus Sutures for preventing surgical site infection), and four new Medtech Innovation Briefings (RapidAI for analyzing CT/MRI brain scans, WoundExpress, Magtrace and Sentimag, and SYNE-COV). Also, four clinical guidelines were updated, and two new published.Read more
In May 2021, the National Institute for Health and Care Excellence (NICE) published five new Interventional Procedure Guidance (ex-situ machine perfusion for extracorporeal preservation of lungs for transplant, transvaginal laser therapy for stress urinary incontinence and for urogenital atrophy, electrohydraulic lithotripsy for difficult-to-treat bile duct stones, and permanent His-bundle pacemaker for heart failure), one new Medical Technologies Guidance (UroLift for benign prostatic hyperplasia), and two new Medtech Innovation Briefings (Axonics sacral neuromodulation system for faecal incontinence and KODEX-EPD for cardiac imaging during ablation of arrhythmias). Also, three clinical guidelines and two Medical Technologies Guidance were updated.Read more
In February 2021, the National Institute for Health and Care Excellence (NICE) published one new medical technologies guidance (Leukomed Sorbact for preventing surgical site infection) and seven new Medtech innovation briefings (PROPEL sinus implants, URO17 for detecting bladder cancer, Faecal microbiota transplant, DOAC Dipstick for detecting oral anticoagulants, CytoSorb for reducing the risk of bleeding during cardiac surgery, and others).Read more
The report presents a summary of the reimbursement situation for the use of negative pressure wound therapy (NPWT) (procedure and medical aid) in Europe. The following clinical indications are considered: diabetic foot ulcer; venous leg ulcer; pressure ulcer. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.Read more